# APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

> **NCT03745716** · PHASE3 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 154 (actual)

## Conditions studied

- MDS

## Interventions

- **DRUG:** APR-246 + azacitidine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03745716
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-11
- **Primary completion:** 2020-11-27
- **Final completion:** 2022-01-14
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745716, "APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03745716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*